News about "Emcure Pharmaceuticals "

Emcure Reports Robust Q1 FY27 Results, PAT Surges 36 Percent

Emcure Pharmaceuticals reported a strong Q1 FY27 with 22.8 percent revenue growth, 36.2 percent higher profit, improved margins, robust performance across key therapies, and over 15 product approvals in global markets.

Emcure Pharmaceuticals | 07/08/2026 | By News Bureau |  113

ICMR Transfers 3 Indigenous Biomedical Technologies

ICMR has transferred 3 indigenous biomedical technologies, including an anti-HPV candidate and enteric vaccines, to accelerate cancer and infectious disease solutions.

Emcure Pharmaceuticals | 23/07/2026 | By News Bureau

Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication

Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.

Emcure Pharmaceuticals | 21/07/2026 | By News Bureau

Emcure Takes Full Ownership of Gennova, Strengthens Focus on Biologics and Biosimilars

Emcure Pharmaceuticals has acquired the remaining minority stake in Gennova Biopharmaceuticals, making it a wholly owned subsidiary while appointing Samit Mehta to lead the company’s next phase of growth in biologics and biosimilars.

Emcure Pharmaceuticals | 14/07/2026 | By News Bureau

Emcure's Marcan Pharma to Acquire Remaining Stake in Mantra Pharma

Emcure Pharmaceuticals' subsidiary Marcan Pharmaceuticals has signed agreements to acquire the remaining Class E Special Shares of Canada's Mantra Pharma, making the company a wholly owned subsidiary.

Emcure Pharmaceuticals | 06/07/2026 | By News Bureau

Emcure Slashes Price of Semaglutide-Based Weight Loss Drug Poviztra in India

Emcure reduces the price of its semaglutide-based drug Poviztra, aiming to make effective weight management treatment more accessible to patients across India.

Emcure Pharmaceuticals | 04/04/2026 | By News Bureau |  183

Emcure Launches Poviztra to Broaden Access to Weight Management Therapy

Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.

Emcure Pharmaceuticals | 22/12/2025 | By News Bureau |  363

Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India

Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.

Emcure Pharmaceuticals | 10/11/2025 | By Dineshwori |  798

Emcure Pharma Delivers Robust Performance Across All Businesses in Q1FY26: Satish Mehta

Emcure Pharmaceuticals reported strong financial results for the first quarter of FY26, demonstrating impressive growth in both domestic and international businesses.

Emcure Pharmaceuticals | 07/08/2025 | By Dineshwori |  566

Sanofi India, Emcure Sign Exclusive Distribution Partnership for Anti-Diabetic Drugs

Sanofi India Ltd. has entered into an exclusive distribution and promotion agreement with Emcure Pharmaceuticals for its oral anti-diabetic brands, including Amaryl and Cetapin, aiming to expand patient access and strengthen diabetes care across India.

Emcure Pharmaceuticals | 17/07/2025 | By Mrinmoy Dey |  422